Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Marginal increase of sunitinib exposure by grapefruit juice.
van Erp NP, Baker SD, Zandvliet AS, Ploeger BA, den Hollander M, Chen Z, den Hartigh J, König-Quartel JM, Guchelaar HJ, Gelderblom H. van Erp NP, et al. Among authors: den hartigh j, den hollander m. Cancer Chemother Pharmacol. 2011 Mar;67(3):695-703. doi: 10.1007/s00280-010-1367-0. Epub 2010 May 29. Cancer Chemother Pharmacol. 2011. PMID: 20512335 Free PMC article. Clinical Trial.
Explaining variability in ciclosporin exposure in adult kidney transplant recipients.
Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt H, Danhof M, de Fijter H, Guchelaar HJ. Press RR, et al. Among authors: den hartigh j. Eur J Clin Pharmacol. 2010 Jun;66(6):579-90. doi: 10.1007/s00228-010-0810-9. Epub 2010 Mar 31. Eur J Clin Pharmacol. 2010. PMID: 20354687 Free PMC article.
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
de Wit D, Gelderblom H, Sparreboom A, den Hartigh J, den Hollander M, König-Quartel JM, Hessing T, Guchelaar HJ, van Erp NP. de Wit D, et al. Among authors: den hartigh j, den hollander m. Cancer Chemother Pharmacol. 2014 Jan;73(1):87-96. doi: 10.1007/s00280-013-2322-7. Epub 2013 Oct 23. Cancer Chemother Pharmacol. 2014. PMID: 24149944
Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.
de Wit D, Schneider TC, Moes DJ, Roozen CF, den Hartigh J, Gelderblom H, Guchelaar HJ, van der Hoeven JJ, Links TP, Kapiteijn E, van Erp NP. de Wit D, et al. Among authors: den hartigh j. Cancer Chemother Pharmacol. 2016 Jul;78(1):63-71. doi: 10.1007/s00280-016-3050-6. Epub 2016 May 11. Cancer Chemother Pharmacol. 2016. PMID: 27169792 Free PMC article. Clinical Trial.
Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J. Cremers S, et al. Among authors: den hartigh j. Br J Clin Pharmacol. 2005 Sep;60(3):249-56. doi: 10.1111/j.1365-2125.2005.02398.x. Br J Clin Pharmacol. 2005. PMID: 16120063 Free PMC article.
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
de Wit D, Guchelaar HJ, den Hartigh J, Gelderblom H, van Erp NP. de Wit D, et al. Among authors: den hartigh j. Drug Discov Today. 2015 Jan;20(1):18-36. doi: 10.1016/j.drudis.2014.09.007. Epub 2014 Sep 22. Drug Discov Today. 2015. PMID: 25245169 Review.
102 results